The Cost of GLP-1 Therapy: Compounded vs Brand vs Insurance
The GLP-1 receptor agonist market has exploded into one of the most commercially significant pharmaceutical categories in history. Novo Nordisk's Wegovy and Ozempic generated over $21 billion in revenue in 2023 alone, while Eli Lilly's tirzepatide products (Mounjaro and Zepbound) are on a trajectory to match those figures. Yet for many patients and researchers, the defining feature of these therapies isn't their efficacy — it's their price tag.
Understanding the financial landscape of GLP-1 therapy requires examining three distinct access pathways: brand-name pharmaceuticals, compounded formulations, and insurance-covered prescriptions. Each carries meaningfully different costs, regulatory considerations, and risk profiles.
Brand-Name Pricing: The Sticker Shock
The list prices for FDA-approved GLP-1 receptor agonists remain among the highest for chronic-use medications. Semaglutide, marketed as Ozempic (for type 2 diabetes) and Wegovy (for obesity), carries a list price of approximately $1,349 per month for Wegovy and around $935 per month for Ozempic, according to GoodRx pricing data.
Tirzepatide, the dual GIP/GLP-1 receptor agonist sold as Mounjaro and Zepbound, has comparable pricing. Zepbound's list price sits at approximately $1,059 per month, while Mounjaro is priced similarly at around $1,023 per month GoodRx, 2024.
These prices reflect the maintenance dose costs. Because both semaglutide and tirzepatide require gradual dose titration over several months, initial costs may be slightly lower. However, therapy is intended to be ongoing — discontinuation has been associated with significant weight regain, as demonstrated in the STEP 1 extension trial, where participants regained approximately two-thirds of lost weight within one year of stopping semaglutide Wilding et al., 2022.
For patients paying entirely out of pocket, annual costs for brand-name GLP-1 therapy range from $12,000 to $16,000 — a figure that puts these medications out of reach for a significant portion of the population.
Insurance Coverage: A Patchwork System
Insurance coverage for GLP-1 agonists varies dramatically depending on the indication, payer, and plan type. Coverage for type 2 diabetes indications is relatively common, as semaglutide and tirzepatide have robust Phase 3 data supporting glycemic control. The SUSTAIN trial program demonstrated that semaglutide reduced HbA1c by 1.5–1.8% across multiple comparator studies Aroda et al., 201730311-6), and tirzepatide showed even larger reductions of up to 2.07% in the SURPASS-1 trial Rosenstock et al., 2021.
Coverage for obesity indications is far more inconsistent. A 2024 KFF analysis found that only roughly 25% of large employer plans explicitly covered anti-obesity medications, though this number is growing KFF, 2024. Medicare Part D has historically been prohibited from covering drugs prescribed solely for weight loss, though recent legislative proposals aim to change this.
Even when insurance covers these medications, patients frequently encounter:
The net result is that even insured patients may face significant financial barriers. Manufacturer savings programs (like Novo Nordisk's and Lilly's copay cards) can reduce costs to as low as $0–$25 per month for commercially insured patients, but these programs exclude government insurance beneficiaries and have annual caps.
Compounded Formulations: The Affordable Alternative
The emergence of compounded semaglutide and tirzepatide has fundamentally disrupted the GLP-1 pricing landscape. Under the FDA's 503A and 503B pathways, compounding pharmacies are permitted to produce copies of drugs that are listed on the FDA's drug shortage list. Both semaglutide and tirzepatide have appeared on this list, opening the door to legal compounded versions.
Compounded semaglutide is widely available at prices ranging from $100 to $400 per month, depending on the dose, pharmacy, and whether the formulation uses semaglutide base or semaglutide sodium salt. Compounded tirzepatide is similarly priced, typically between $150 and $500 per month at maintenance doses.
These represent savings of 60–90% compared to brand-name pricing, which has driven enormous demand. However, the compounding landscape carries important caveats that researchers and consumers should understand.
Regulatory and Quality Considerations
The FDA has issued multiple warnings about compounded GLP-1 products. In a 2023 safety communication, the agency noted that compounded versions are not FDA-approved, meaning they have not undergone the same rigorous testing for safety, efficacy, and bioequivalence as brand-name products.
Key concerns include:
A study by Rinella et al., 2024 analyzing compounded GLP-1 products found that some samples contained less active ingredient than labeled, while others contained impurities not present in FDA-approved formulations.
503B outsourcing facilities, which operate under stricter FDA oversight than traditional 503A compounding pharmacies, generally offer higher quality assurance. Researchers evaluating compounded peptides should prioritize facilities that provide certificates of analysis (COAs) with third-party verification.
The Shortage Question and Future Pricing
The legality of compounded GLP-1 products hinges on the FDA's drug shortage list. In October 2024, the FDA announced that tirzepatide was no longer in shortage, which legally obligates compounding pharmacies to cease production of compounded tirzepatide FDA, 2024. This triggered immediate legal challenges from compounding industry groups.
Semaglutide remains on the shortage list as of early 2025, but supply conditions are improving. If semaglutide is also resolved from the shortage list, the compounded market would face significant contraction.
In response to pricing pressure, both manufacturers have introduced some cost-reduction measures. Novo Nordisk has offered a direct-to-consumer option through digital health platforms, and Eli Lilly launched single-dose vials of tirzepatide at roughly $399 for a month's supply at the lowest dose through its LillyDirect program Eli Lilly, 2024.
Cost-Effectiveness Research
Beyond individual out-of-pocket costs, health economic analyses have attempted to determine whether GLP-1 therapies are cost-effective from a system-wide perspective. A modeling study published in Annals of Internal Medicine estimated that semaglutide for obesity would need to be priced at approximately $3,500 per year (roughly one-quarter of current list price) to meet conventional cost-effectiveness thresholds of $100,000 per quality-adjusted life year Hernandez et al., 2022.
The SURMOUNT-1 trial demonstrated that tirzepatide achieved 22.5% mean body weight reduction at the highest dose Jastreboff et al., 2022, and the SELECT cardiovascular outcomes trial showed semaglutide reduced major adverse cardiovascular events by 20% in people with obesity Lincoff et al., 2023. These outcomes strengthen the health-economic argument for broader coverage, but current pricing remains a barrier.